Skip to content
value.today

Biotelemetry

BEAT
$34 Mmarket cap on Oct 30, 2026-45.7% since Jan 2024
Compare
World rank
#22,587
Revenue
—
For year ending December-2025
Net income
$-21 M
SEC filing
Employees
1,500
As of 2020
value.today research

Biotelemetry in brief

Biotelemetry is a listed company in the Healthcare sector, based in Pennsylvania, USA. Its market value was $34 M on 30 October 2026, which makes it the 22,587th largest listed company in the world and the 3,998th largest in the USA on this site. It employs about 1,500 people. Its shares trade under the symbol BEAT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Biotelemetry

BioTelemetry is the Mobile and Wireless Medical Technology Industry. It has focus on the delivery of health information to save and improve lives while reducing the cost of care. The Company provides cardiac and mobile blood glucose monitoring, centralized medical imaging and original equipment manufacturing serving the healthcare and clinical research sectors. The headquarters is in USA.

Biotelemetry timeline

2 events, 2019–2021
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 November 2021; shares registered for exchange trading on 10 November 2021.

Events of Biotelemetry from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$668 M$1.3 B$2.0 B$2.7 B2020202120222023202420252026

World rank over time

▼ down 16,725 places since 2020
2020-01-01: #5895#5,89520202021-01-01: #4840#4,84020212022-01-07: #30287#30,28720222022-12-25: #26844#26,84420222023-07-30: #22945#22,94520232024-01-05: #23763#23,76320242026-03-08: #10806#10,80620262026-08-01: #21004#21,00420262026-10-09: #22984#22,98420262026-10-30: #22620#22,6202026

Rank in USA: #1,717 (Jan 2020) · #1,506 (Jan 2021) · #5,237 (Jan 2022) · #4,992 (Dec 2022) · #4,418 (Jul 2023) · #3,947 (Jan 2024) · #2,115 (Mar 2026) · #3,883 (Aug 2026) · #4,011 (Oct 2026) · #4,001 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
13.1×
Free cash flow yield
-42.7%
Net margin
—
Operating margin
—
Return on equity
-808.5%
Liabilities / assets
55.5%
Profit per employee
$-14 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-1M—FY20Fiscal year ending Dec 2021: revenue —, net income $-4M—FY21Fiscal year ending Dec 2022: revenue —, net income $-13M—FY22Fiscal year ending Dec 2023: revenue —, net income $-15M—FY23Fiscal year ending Dec 2024: revenue —, net income $-19M—FY24Fiscal year ending Dec 2025: revenue —, net income $-21M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-21M$-21M—
Dec 2024——$-20M$-19M—
Dec 2023——$-15M$-15M—
Dec 2022——$-13M$-13M—
Dec 2021——$-2M$-4M—
Dec 2020——$-1M$-1M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M$1M$-15M$-0.62—
Dec 2024$-14M$0M$-15M$-0.73—
Dec 2023$-12M$0M$-12M$-0.72—
Dec 2022$-10M$0M$-10M$-1.59—
Dec 2021$-3M——$-1.03—
Dec 2020$-1M——$-0.29—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-5M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue —, net income $-5M—Jun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-3M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Biotelemetry with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-21 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$6 M
Total liabilities
$3 M
Total equity
$3 M

As of December-2025

Top 39 institutional investors in Biotelemetry#

As of Sep 30, 2026
39 institutions held 8.0 M shares (about 12.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 10.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Biotelemetry
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC2,137,5120 (0.00%)3.38%$1 MNov 13, 2026
2BlackRock, Inc.980,669-7,168 (-0.73%)1.55%$0 MNov 13, 2026
3Corsair Capital Management, L.P.662,500-250,000 (-27.40%)1.05%$0 MNov 16, 2026
4Bleichroeder LP625,0000 (0.00%)0.99%$0 MNov 13, 2026
5Geode Capital Management, LLC480,465+1,079 (+0.23%)0.76%$0 MNov 6, 2026
6Sigma Planning Corp387,200+139,500 (+56.32%)0.61%$0 MOct 23, 2026
7Smith Salley Wealth Management367,6470 (0.00%)0.58%$0 MNov 3, 2026
8O'shaughnessy Asset Management, LLC280,161+71,970 (+34.57%)0.44%$0 MNov 12, 2026
9Ritholtz Wealth Management280,161+71,970 (+34.57%)0.44%$0 MNov 5, 2026
10Vanguard Fiduciary Trust Co274,8180 (0.00%)0.43%$0 MNov 13, 2026
11Beacon Pointe Advisors, LLC247,0580 (0.00%)0.39%$0 MNov 16, 2026
12UBS Group AG229,107-69,810 (-23.35%)0.36%$0 MNov 10, 2026
13Kestra Private Wealth Services, LLC170,439-3,000 (-1.73%)0.27%$0 MNov 6, 2026
14State Street Corp125,4730 (0.00%)0.20%$0 MNov 12, 2026
15Northern Trust Corp101,1290 (0.00%)0.16%$0 MNov 16, 2026
16Spectrum Asset Management, Inc. (NB/CA)100,4000 (0.00%)0.16%$0 MOct 19, 2026
17Cannon Financial Strategists, Inc.92,645+19,857 (+27.28%)0.15%$0 MOct 19, 2026
18XTX Topco Ltd78,914+24,640 (+45.40%)0.12%$0 MNov 16, 2026
19HRT Financial LP62,333New0.10%$0 MNov 13, 2026
20Morgan Stanley57,0450 (0.00%)0.09%$0 MNov 13, 2026
21Stifel Financial Corp51,0000 (0.00%)0.08%$0 MNov 12, 2026
22Advisory Research Inc50,0000 (0.00%)0.08%$0 MNov 12, 2026
23Raymond James Financial Inc40,210-94,224 (-70.09%)0.06%$0 MNov 12, 2026
24CIBC Bancorp USA Inc.20,6310 (0.00%)0.03%$0 MNov 13, 2026
25Tower Research Capital LLC (TRC)19,717+15,408 (+357.58%)0.03%$0 MNov 16, 2026
Show all 39: investors 26 to 39
Institutional investors 26 to 39 in Biotelemetry
#InstitutionShares heldChange (shares)% heldValueFiled
26Truist Financial Corp15,0000 (0.00%)0.02%$0 MOct 30, 2026
27Vanguard Global Advisers, LLC13,3080 (0.00%)0.02%$0 MNov 13, 2026
28Farther Finance Advisors, LLC12,000+6,000 (+100.00%)0.02%$0 MOct 8, 2026
29J.W. Cole Advisors, Inc.11,0000 (0.00%)0.02%$0 MNov 5, 2026
30Commonwealth Equity Services, LLC10,7230 (0.00%)0.02%$0 MNov 2, 2026
31Two Sigma Securities, LLC10,360New0.02%$0 MNov 16, 2026
32HB Wealth Management, LLC10,0000 (0.00%)0.02%$0 MOct 23, 2026
33Nuveen, LLC7,773New0.01%$0 MNov 10, 2026
34Harbour Investments, Inc.5,750-3,000 (-34.29%)0.01%$0 MNov 9, 2026
35Blue Trust, Inc.1,9280 (0.00%)0.00%$0 MOct 15, 2026
36Larson Financial Group LLC1,2500 (0.00%)0.00%$0 MNov 5, 2026
37Wells Fargo & Company/mn1,0000 (0.00%)0.00%$0 MNov 16, 2026
38NewEdge Advisors, LLC1,0000 (0.00%)0.00%$0 MNov 13, 2026
39Osaic Holdings, Inc.1,0000 (0.00%)0.00%$0 MNov 12, 2026

Mutual funds holding Biotelemetry#

10 funds hold shares worth $2 M (about 4.1% of the company). Since their previous reports 9 added shares and 1 sold, buying $1 M net.
Mutual funds holding Biotelemetry
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.45 M$1 M2.3%<0.01%+92%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.656,120$0 M1.0%<0.01%+100%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC178,950$0 M0.28%<0.01%+19%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors155,600$0 M0.25%<0.01%+123%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC47,501$0 M0.08%<0.01%+23%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC44,849$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.32,990$0 M0.05%<0.01%+40%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC24,817$0 M0.04%<0.01%+51%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,462$0 M0.02%<0.01%+109%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,199$0 M<0.01%<0.01%+78%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Biotelemetry#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$855 K
8 purchases, 8 insiders
Sold, 12 months
$1.1 M
3 sales, 2 insiders
Net, 12 months
-$222 K
open market only
Insiders on file
16
since
$855 K-$1.1 M$0Aug 2024: bought $0 (0 trades), sold $24 K (4 trades)Aug 24Sep 2024: bought $0 (0 trades), sold $4 K (1 trades)SepFeb 2025: bought $80 K (2 trades), sold $0 (0 trades)FebDec 2025: bought $0 (0 trades), sold $1.1 M (3 trades)DecApr 2026: bought $855 K (8 trades), sold $0 (0 trades)Apr
Bought (open market)Sold (open market)Hover a month for the totals
Biotelemetry: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kenneth Harry PersenChief Technology OfficerGrant or award+105,740——448,290Form 4
filed Tim CruickshankCFOGrant or award+167,760——239,990Form 4
filed Branislav VajdicPresident, DirectorGrant or award+260,870——3.97 MForm 4
filed Branislav VajdicPresident, DirectorGrant or award+2.80 M——3.71 MForm 4
filed Richard FerrariDirectorBuyamended+57,500$0.800$46 K286,636Form 4/A
filed Branislav VajdicDirectorBuy+31,250$0.800$25 K909,914Form 4
filed Tim CruickshankCFOBuy+31,250$0.800—72,230Form 4
filed Richard FerrariDirectorBuy+62,500$0.800$50 K291,636Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Biotelemetry#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.3 M
5.7% of shares · 1.6 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-2.75 reverse split

Trading halts

  • 2025-11-21 15:32 UTC, code LUDP, resumed 15:37 UTC

Fails to deliver

  • : 41,259 shares at $0.54
  • : 135,957 shares at $0.53
  • : 17,825 shares at $0.41
  • : 311,814 shares at $0.49
  • : 12,908 shares at $0.58

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Biotelemetry scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median13.2×Price to book 13.2× against Healthcare's median of 3.1×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-42.7%Free cash flow is -42.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.62 vs -0.73Diluted EPS -0.62 in fiscal 2025 against -0.73 the year before (report's currency).
    • ✗Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$1 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-989.2%-989.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.44 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year26.5%Diluted shares up 26.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Biotelemetry: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Biotelemetry: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development13,45011,0516,7985,677255133
General and administrative7,6898,8368,5167,3542,030655
Operating expenses21,13919,88715,31413,0312,285788
Operating income−21,139−19,887−15,314−13,031−2,285−788
Interest expense and finance costs————2,165280
Other non-operating income (expense)12443967569−2,143−280
Income before tax−21,015−19,448−14,639−12,962−4,428−1,068
Income tax000000
Net income attributable to shareholders−21,015−19,448−14,639−12,962−4,428−1,068
Earnings per share, basic-0.62-0.73-0.72-1.59-1.03-0.29
Earnings per share, diluted-0.62-0.73-0.72-1.59-1.03-0.29
Shares, weighted average (basic)3427208.24.33.6
Shares, weighted average (diluted)3427208.24.33.6
Balance sheet
Cash and cash equivalents4,3802,37716,1893,59413,19224
Inventory1030————
Other current assets20239363644580627
Current assets4,6852,77016,8254,039——
Property, plant and equipment1,1024502560——
Total assets5,8433,27617,1314,03913,99851
Accounts payable1,053531556r1,665588489
Current liabilities3,2401,6221,194——4,836
Total liabilities3,2401,6221,1941,6655884,836
Retained earnings−77,288−56,273−36,825−22,186−9,224−4,796
Shareholders' equity2,6031,65415,9372,37413,410−4,785
Total liabilities and equity5,8433,27617,1314,03913,99851
Shares outstanding40r27r268.07.83.5
Cash-flow statement
Share-based compensation5,1474,2993,2081,12019210
Cash from operating activities−13,988−14,471−12,093−9,948−3,230−600
Capital expenditure−600−201−2560——
Cash from investing activities−600−201−2560——
Shares issued—73024,76434814,713—
Cash from financing activities16,59186624,99435016,398619
Change in cash2,003−13,80612,645−9,59813,16819
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Biotelemetry#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 1 · Auditor changed 1 · Directors and officers 9 · Material agreement 4 · Agreement ended 1 · Shareholder vote 4

Biotelemetry: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Directors and officers8-K/A
Shareholder vote8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Auditor changed8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Material agreementAgreement ended8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026

H-1B hiring at Biotelemetry#

3 labor condition applications certified in fiscal 2025 for 3 positions, at a median wage of $229 K a year.

Certified, FY2025
3
#1,408 among companies on value.today
Worker positions
3
Median wage offered
$229 K
a year, full-time
Applications filed
3
Biotelemetry: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Director of Platform ITComputer and Information Systems Managers1$229 K
Sr. Software EngineerSoftware Developers1$144 K
Vice President, Software EngineeringComputer and Information Systems Managers1$245 K

Where: South Jordan, UT 1 · Brea, CA 1 · Foothill Ranch, CA 1

Biotelemetry: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202533$229 K3
FY202411$220 K1
FY202311$103 K1
FY202211$217 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as HeartBeam, Inc.

How Biotelemetry compares in Healthcare

  • Market cap$34 M · higher than 17% of 2,013
  • Price / book13.2× · lower than 10% of 1,245
  • FCF yield-42.7% · higher than 20% of 835
CompanyMarket capP/ENet marginRev. growth
Biotelemetry🇺🇸$34 M———
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of 2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Biotelemetry? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Biotelemetry's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Biotelemetry? Suggest a correction